Neurodegeneration with brain iron accumulation: Update on pathogenic mechanisms

Frontiers in Pharmacology

Volumn 5 MAY, Issue , 2014, Pages

  Levi, Sonia ^a,b   Finazzi, Dario ^c,d  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d SPEDALI CIVILI   (Italy)

Author keywords

Brain; Iron; NBIA disorders; Neurodegeneration; Oxidative stress; Pathogenesis

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); BETA PROPELLER PROTEIN; CERULOPLASMIN; FATTY ACID SYNTHASE; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; MEMBRANE PROTEIN; MITOCHONDRIAL MEMBRANE PROTEIN; PANTOTHENATE KINASE 2; PHOSPHOLIPASE; PHOSPHOLIPASE 2; PHOSPHOLIPASE A2; PROTEIN; UNCLASSIFIED DRUG;

ACERULOPLASMINEMIA; ATP13A2 GENE; AUTOPHAGOSOME; C19ORF12 GENE; C2ORF37 GENE; CLINICAL FEATURE; COASY GENE; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; FA2H GENE; FTL GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; IRON METABOLISM; KUFOR RAKEB DISEASE; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFERRITINOPATHY; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PANK2 GENE; PLA2G GENE; REVIEW; WDR45 GENE;

EID: 84904622975     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00099     Document Type: Review

References (176)

1. Abbruzzese, G., Cossu, G., Balocco, M., Marchese, R., Murgia, D., Melis, M., et al. (2011). A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 96, 1708-1711. doi: 10.3324/haematol.2011.043018
2. Ackermann, E. J., Kempner, E. S., and Dennis, E. A. (1994). Ca(2+)-independent cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization. J. Biol. Chem. 269, 9227-9233.
3. Afshar, K., Gönczy, P., DiNardo, S., and Wasserman, S. A. (2001). fumble encodes a pantothenate kinase homolog required for proper mitosis and meiosis in Drosophila melanogaster. Genetics 157, 1267-1276.
4. Alfonso-Pecchio, A., Garcia, M., Leonardi, R., and Jackowski, S. (2012). Compartmentalization of mammalian pantothenate kinases. PLoS ONE 7:e49509. doi: 10.1371/journal.pone.0049509
5. Allen, G. F., Toth, R., James, J., and Ganley, I. G. (2013). Loss of iron triggers PINK1/Parkin-independent mitophagy. EMBO Rep. 14, 1127-1135. doi: 10.1038/embor.2013.168
6. Arosio, P., and Levi, S. (2010). Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim. Biophys. Acta 1800, 783-792. doi: 10.1016/j.bbagen.2010.02.005
7. Balboa, M. A., Pérez, R., and Balsinde, J. (2008). Calcium-independent phospholipase A2 mediates proliferation of human promonocytic U937 cells. FEBS J. 275, 1915-1924. doi: 10.1111/j.1742-4658.2008.06350.x
8. Balboa, M. A., Varela-Nieto, I., Killermann Lucas, K., and Dennis, E. A. (2002). Expression and function of phospholipase A(2) in brain. FEBS Lett. 531, 12-17. doi: 10.1016/S0014-5793(02)03481-6
9. Balsinde, J., and Dennis, E. A. (1997). Function and inhibition of intracellular calcium-independent phospholipase A2. J. Biol. Chem. 272, 16069-16072. doi: 10.1074/jbc.272.26.16069
10. Bao, S., Miller, D. J., Ma, Z., Wohltmann, M., Eng, G., Ramanadham, S., et al. (2004). Male mice that do not express group VIA phospholipase A2 produce spermatozoa with impaired motility and have greatly reduced fertility. J. Biol. Chem. 279, 38194-38200. doi: 10.1074/jbc.M406489200
11. Baraibar, M. A., Barbeito, A. G., Muhoberac, B. B., and Vidal, R. (2008). Iron-mediated aggregation and a localized structural change characterize ferritin from a mutant light chain polypeptide that causes neurodegeneration. J. Biol. Chem. 283, 31679-31689. doi: 10.1074/jbc.M805532200
12. Baraibar, M. A., Barbeito, A. G., Muhoberac, B. B., and Vidal, R. (2012). A mutant light-chain ferritin that causes neurodegeneration has enhanced propensity toward oxidative damage. Free Radic. Biol. Med. 52, 1692-1697. doi: 10.1016/j.freeradbiomed.2012.02.015
13. Baraibar, M. A., Muhoberac, B. B., Garringer, H. J., Hurley, T. D., and Vidal, R. (2010). Unraveling of the E-helices and disruption of 4-fold pores are associated with iron mishandling in a mutant ferritin causing neurodegeneration. J. Biol. Chem. 285, 1950-1956. doi: 10.1074/jbc.M109.042986
14. Barbeito, A. G., Garringer, H. J., Baraibar, M. A., Gao, X., Arredondo, M., Nunez, M. T., et al. (2009). Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene. J. Neurochem. 109, 1067-1078. doi: 10.1111/j.1471-4159.2009.06028.x
15. Barbeito, A. G., Levade, T., Delisle, M. B., Ghetti, B., and Vidal, R. (2010). Abnormal iron metabolism in fibroblasts from a patient with the neurodegenerative disease hereditary ferritinopathy. Mol. Neurodegener. 5:50. doi: 10.1186/1750-1326-5-50
16. Beck, G., Sugiura, Y., Shinzawa, K., Kato, S., Setou, M., Tsujimoto, Y., et al. (2011). Neuroaxonal dystrophy in calcium-independent phospholipase A2ß deficiency results from insufficient remodeling and degeneration of mitochondrial and presynaptic membranes. J. Neurosci. 31, 11411-11420. doi: 10.1523/JNEUROSCI.0345-11.2011
17. Behrends, C., Sowa, M. E., Gygi, S. P., and Harper, J. W. (2010). Network organization of the human autophagy system. Nature 466, 68-76. doi: 10.1038/nature09204
18. Bosveld, F., Rana, A., van der Wouden, P. E., Lemstra, W., Ritsema, M., Kampinga, H. H., et al. (2008). De novo CoA biosynthesis is required to maintain DNA integrity during development of the Drosophila nervous system. Hum. Mol. Genet. 17, 2058-2069. doi: 10.1093/hmg/ddn105
19. Bras, J., Verloes, A., Schneider, S. A., Mole, S. E., and Guerreiro, R. J. (2012). Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum. Mol. Genet. 21, 2646-2650. doi: 10.1093/hmg/dds089
20. Brissot, P., Ropert, M., Le Lan, C., and Loreal, O. (2012). Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim. Biophys. Acta 1820, 403-410. doi: 10.1016/j.bbagen.2011.07.014
21. Brunetti, D., Dusi, S., Giordano, C., Lamperti, C., Morbin, M., Fugnanesi, V., et al. (2014). Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model. Brain 137(Pt 1), 57-68. doi: 10.1093/brain/awt325
22. Brunetti, D., Dusi, S., Morbin, M., Uggetti, A., Moda, F., D'Amato, I., et al. (2012). Pantothenate kinase-associated neurodegeneration: altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model. Hum. Mol. Genet. 21, 5294-5305. doi: 10.1093/hmg/dds380
23. Burke, J. E., and Dennis, E. A. (2009). Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res. 50(Suppl.), S237-S242. doi: 10.1194/jlr.R800033-JLR200
24. Campanella, A., Privitera, D., Guaraldo, M., Rovelli, E., Barzaghi, C., Garavaglia, B., et al. (2012). Skin fibroblasts from pantothenate kinase-associated neurodegeneration patients show altered cellular oxidative status and have defective iron-handling properties. Hum. Mol. Genet. 21, 4049-4059. doi: 10.1093/hmg/dds229
25. Chinnery, P. F., Crompton, D. E., Birchall, D., Jackson, M. J., Coulthard, A., Lombes, A., et al. (2007). Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130(Pt 1), 110-119. doi: 10.1093/brain/awl319
26. Cowen, D., and Olmstead, E. V. (1963). Infantile neuroaxonal dystrophy. J. Neuropathol. Exp. Neurol. 22, 175-236.
27. Cozzi, A., Rovelli, E., Frizzale, G., Campanella, A., Amendola, M., Arosio, P., et al. (2010). Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol. Dis. 37, 77-85. doi: 10.1016/j.nbd.2009.09.009
28. Cozzi, A., Santambrogio, P., Corsi, B., Campanella, A., Arosio, P., and Levi, S. (2006). Characterization of the L-ferritin variant 460InsA responsible of a hereditary ferritinopathy disorder. Neurobiol. Dis. 23, 644-652. doi: 10.1016/j.nbd.2006.05.004
29. Crompton, D. E., Chinnery, P. F., Fey, C., Curtis, A. R., Morris, C. M., Kierstan, J., et al. (2002). Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol. Dis. 29, 522-531. doi: 10.1006/bcmd.2002.0589
30. Crompton, D., Rehal, P. K., MacPherson, L., Foster, K., Lunt, P., Hughes, I., et al. (2010). Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: implications for molecular diagnosis. Mol. Genet. Metab. 100, 207-212. doi: 10.1016/j.ymgme.2010.02.009
31. Cui, R., Duan, X. L., Anderson, G. J., Qiao, Y. T., Yu, P., Qian, Z. M., et al. (2009). Age-dependent expression of hephaestin in the brain of ceruloplasmin-deficient mice. J. Trace Elem. Med. Biol. 23, 290-299. doi: 10.1016/j.jtemb.2009.05.004
32. Curtis, A. R., Fey, C., Morris, C. M., Bindoff, L. A., Ince, P. G., Chinnery, P. F., et al. (2001). Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28, 350-354. doi: 10.1038/ng571
33. Dehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M. H., Doudnikoff, E., et al. (2012). Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 109, 9611-9616. doi: 10.1073/pnas.1112368109
34. Deng, X., Vidal, R., and Englander, E. W. (2010). Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy. Neurosci. Lett. 479, 44-48. doi: 10.1016/j.neulet.2010.05.025
35. Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., et al. (2014). Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal. doi: 10.1089/ars.2013.5593 [Epub ahead of print].
36. Devos, D., Tchofo, P. J., Vuillaume, I., Destée, A., Batey, S., Burn, J., et al. (2009). Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. Brain 132(Pt 6):e109. doi: 10.1093/brain/awn274
37. Dezortova, M., Herynek, V., Krssak, M., Kronerwetter, C., Trattnig, S., and Hajek, M. (2012). Two forms of iron as an intrinsic contrast agent in the basal ganglia of PKAN patients. Contrast Media Mol. Imaging 7, 509-515. doi: 10.1002/cmmi.1482
38. Dick, K. J., Eckhardt, M., Paisán-Ruiz, C., Alshehhi, A. A., Proukakis, C., Sibtain, N. A., et al. (2010). Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum. Mutat. 31, E1251-E1260. doi: 10.1002/humu.21205
39. di Patti, M. C., Maio, N., Rizzo, G., De Francesco, G., Persichini, T., Colasanti, M., et al. (2009). Dominant mutants of ceruloplasmin impair the copper loading machinery in aceruloplasminemia. J. Biol. Chem. 284, 4545-4554. doi: 10.1074/jbc.M805688200
40. Dusek, P., Dezortova, M., and Wuerfel, J. (2013). Imaging of iron. Int. Rev. Neurobiol. 110, 195-239. doi: 10.1016/B978-0-12-410502-7.00010-7
41. Dusek, P., and Schneider, S. A. (2012). Neurodegeneration with brain iron accumulation. Curr. Opin. Neurol. 25, 499-506. doi: 10.1097/WCO.0b013e3283550cac
42. Dusek, P., and Schneider, S. A. (2013). Neurodegenerative disorder with brain iron accumulation previously known as SENDA syndrome now genetically determined. Mov. Disord. 28, 1051-1052. doi: 10.1002/mds.25424
43. Dusi, S., Valletta, L., Haack, T. B., Tsuchiya, Y., Venco, P., Pasqualato, S., et al. (2014). Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 94, 11-22. doi: 10.1016/j.ajhg.2013.11.008
44. Edvardson, S., Hama, H., Shaag, A., Gomori, J. M., Berger, I., Soffer, D., et al. (2008). Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am. J. Hum. Genet. 83, 643-648. doi: 10.1016/j.ajhg.2008.10.010
45. Engel, L. A., Jing, Z. O'Brien, D. E., Sun, M., and Kotzbauer, P. T. (2010). Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism. PLoS ONE 5:e12897. doi: 10.1371/journal.pone.0012897
46. Farina, L., Nardocci, N., Bruzzone, M. G., D'Incerti, L., Zorzi, G., Verga, L., et al. (1999). Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients. Neuroradiology 41, 376-380.
47. Finkenstedt, A., Wolf, E., Hofner, E., Gasser, B. I., Bosch, S., Bakry, R., et al. (2010). Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J. Hepatol. 53, 1101-1107. doi: 10.1016/j.jhep.2010.04.039
48. Fischer, A., Sananbenesi, F., Mungenast, A., and Tsai, L. H. (2010). Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 31, 605-617. doi: 10.1016/j.tips.2010.09.003
49. Forni, G. L., Balocco, M., Cremonesi, L., Abbruzzese, G., Parodi, R. C., and Marchese, R. (2008). Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov. Disord. 23, 904-907. doi: 10.1002/mds.22002
50. Galvin, J. E., Giasson, B., Hurtig, H. I., Lee, V. M., and Trojanowski, J. Q. (2000). Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am. J. Pathol. 157, 361-368.
51. Garcia, M., Leonardi, R., Zhang, Y. M., Rehg, J. E., and Jackowski, S. (2012). Germline deletion of pantothenate kinases 1 and 2 reveals the key roles for CoA in postnatal metabolism. PLoS ONE 7:e40871. doi: 10.1371/journal.pone.0040871
52. Gonzalez-Cuyar, L. F., Perry, G., Miyajima, H., Atwood, C. S., Riveros-Angel, M., Lyons, P. F., et al. (2008). Redox active iron accumulation in aceruloplasminemia. Neuropathology 28, 466-471. doi: 10.1111/j.1440-1789.2008.00901.x
53. Green, J. T., Orr, S. K., and Bazinet, R. P. (2008). The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids. J. Lipid Res. 49, 939-944. doi: 10.1194/jlr.R700017-JLR200
54. Gregory, A., and Hayflick, S. J. (2011). Genetics of neurodegeneration with brain iron accumulation. Curr. Neurol. Neurosci. Rep. 11, 254-261. doi: 10.1007/s11910-011-0181-3
55. Gregory, A., Polster, B. J., and Hayflick, S. J. (2009). Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J. Med. Genet. 46, 73-80. doi: 10.1136/jmg.2008.061929
56. Gregory, A., Westaway, S. K., Holm, I. E., Kotzbauer, P. T., Hogarth, P., Sonek, S., et al. (2008). Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 71, 1402-1409. doi: 10.1212/01.wnl.0000327094.67726.28
57. Grünewald, A., Arns, B., Seibler, P., Rakovic, A., Münchau, A., Ramirez, A., et al. (2012). ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome. Neurobiol. Aging 33, 1843.e1-1843.e7. doi: 10.1016/j.neurobiolaging.2011.12.035
58. Haack, T. B., Hogarth, P., Kruer, M. C., Gregory, A., Wieland, T., Schwarzmayr, T., et al. (2012). Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am. J. Hum. Genet. 91, 1144-1149. doi: 10.1016/j.ajhg.2012.10.019
59. Hadziahmetovic, M., Dentchev, T., Song, Y., Haddad, N., He, X., Hahn, P., et al. (2008). Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. Invest. Ophthalmol. Vis. Sci. 49, 2728-2736. doi: 10.1167/iovs.07-1472
60. Hadziahmetovic, M., Song, Y., Wolkow, N., Iacovelli, J., Grieco, S., Lee, J., et al. (2011). The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration. Invest. Ophthalmol. Vis. Sci. 52, 959-968. doi: 10.1167/iovs.10-6207
61. Hahn, P., Qian, Y., Dentchev, T., Chen, L., Beard, J., Harris, Z. L., et al. (2004). Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 101, 13850-13855. doi: 10.1073/pnas.0405146101
62. Harris, Z. L., Durley, A. P., Man, T. K., and Gitlin, J. D. (1999). Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc. Natl. Acad. Sci. U.S.A. 96, 10812-10817.
63. Hartig, M. B., Hörtnagel, K., Garavaglia, B., Zorzi, G., Kmiec, T., Klopstock, T., et al. (2006). Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann. Neurol. 59, 248-256. doi: 10.1002/ana.20771
64. Hartig, M. B., Iuso, A., Haack, T., Kmiec, T., Jurkiewicz, E., Heim, K., et al. (2011). Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 89, 543-550. doi: 10.1016/j.ajhg.2011.09.007
65. Hayflick, S. J., Kruer, M. C., Gregory, A., Haack, T. B., Kurian, M. A., Houlden, H. H., et al. (2013). ß-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain 136(Pt 6), 1708-1717. doi: 10.1093/brain/awt095
66. Hayflick, S. J., Westaway, S. K., Levinson, B., Zhou, B., Johnson, M. A., Ching, K. H., et al. (2003). Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N. Engl. J. Med. 348, 33-40. doi: 10.1056/NEJMoa020817
67. Hellman, N. E., Kono, S., Miyajima, H., and Gitlin, J. D. (2002). Biochemical analysis of a missense mutation in aceruloplasminemia. J. Biol. Chem. 277, 1375-1380. doi: 10.1074/jbc.M109123200
68. Hogarth, P., Gregory, A., Kruer, M. C., Sanford, L., Wagoner, W., Natowicz, M. R., et al. (2013). New NBIA subtype: genetic, clinical, pathologic, and radiographic features of MPAN. Neurology 80, 268-275. doi: 10.1212/WNL.0b013e31827e07be
69. Hooks, S. B., and Cummings, B. S. (2008). Role of Ca2+-independent phospholipase A2 in cell growth and signaling. Biochem. Pharmacol. 76, 1059-1067. doi: 10.1016/j.bcp.2008.07.044
70. Hörtnagel, K., Prokisch, H., and Meitinger, T. (2003). An isoform of hPANK2, deficient in pantothenate kinase-associated neurodegeneration, localizes to mitochondria. Hum. Mol. Genet. 12, 321-327.
71. Huang, M. L., Lane, D. J., and Richardson. D. R. (2011). Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid. Redox. Signal. 15, 3003-3019. doi: 10.1089/ars.2011.3921
72. Itoh, K., Negishi, H., Obayashi, C., Hayashi, Y., Hanioka, K., Imai, Y., et al. (1993). Infantile neuroaxonal dystrophy - immunohistochemical and ultrastructural studies on the central and peripheral nervous systems in infantile neuroaxonal dystrophy. Kobe J. Med. Sci. 39, 133-146.
73. Iuso, A., Sibon, O. C., Gorza, M., Heim, K., Organisti, C., Meitinger, T., et al. (2014). Impairment of Drosophila orthologs of the human orphan protein C19orf12 induces bang sensitivity and neurodegeneration. PLoS ONE 9:e89439. doi: 10.1371/journal.pone.0089439
74. Jeong, S. Y., and David, S. (2003). Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 278, 27144-27148. doi: 10.1074/jbc.M301988200
75. Jeong, S. Y., and David, S. (2006). Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice. J. Neurosci. 26, 9810-9819. doi: 10.1523/JNEUROSCI.2922-06.2006
76. Johnson, M. A., Kuo, Y. M., Westaway, S. K., Parker, S. M., Ching, K. H., Gitschier, J., et al. (2004). Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann. N. Y. Acad. Sci. 1012, 282-298. doi: 10.1196/annals.1306.023
77. Kaneko, K., Hineno, A., Yoshida, K., Ohara, S., Morita, H., and Ikeda, S. (2012). Extensive brain pathology in a patient with aceruloplasminemia with a prolonged duration of illness. Hum. Pathol. 43, 451-456. doi: 10.1016/j.humpath.2011.05.016
78. Kono, S. (2012). Aceruloplasminemia. Curr. Drug Targets 13, 1190-1199.
79. Kono, S. (2013). Aceruloplasminemia: an update. Int. Rev. Neurobiol. 110, 125-151. doi: 10.1016/B978-0-12-41-0502-7.00007-7
80. Kono, S., and Miyajima, H. (2006). Molecular and pathological basis of aceruloplasminemia. Biol. Res. 39, 15-23. doi: 10.4067/S0716-97602006000100003
81. Kono, S., Suzuki, H., Oda, T., Miyajima, H., Takahashi, Y., Shirakawa, K., et al. (2006). Biochemical features of ceruloplasmin gene mutations linked to aceruloplasminemia. Neuromol. Med. 8, 361-374. doi: 10.1385/NMM:8:3:361
82. Kono, S., Suzuki, H., Oda, T., Shirakawa, K., Takahashi, Y., Kitagawa, M., et al. (2007). Cys-881 is essential for the trafficking and secretion of truncated mutant ceruloplasmin in aceruloplasminemia. J. Hepatol. 47, 844-850. doi: 10.1016/j.jhep.2007.05.013
83. Kono, S., Yoshida, K., Tomosugi, N., Terada, T., Hamaya, Y., Kanaoka, S., et al. (2010). Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin. Biochim. Biophys. Acta 1802, 968-975. doi: 10.1016/j.bbadis.2010.07.011
84. Kotzbauer, P. T., Truax, A. C., Trojanowski, J. Q., and Lee, V. M. (2005). Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J. Neurosci. 25, 689-698. doi: 10.1523/JNEUROSCI.4265-04.2005
85. Kruer, M. C., and Boddaert, N. (2012). Neurodegeneration with brain iron accumulation: a diagnostic algorithm. Semin. Pediatr. Neurol. 19, 67-74. doi: 10.1016/j.spen.2012.04.001
86. Kruer, M. C., Hiken, M., Gregory, A., Malandrini, A., Clark, D., Hogarth, P., et al. (2011). Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 134(Pt 4), 947-958. doi: 10.1093/brain/awr042
87. Kruer, M. C., Paisán-Ruiz, C., Boddaert, N., Yoon, M. Y., Hama, H., Gregory, A., et al. (2010). Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann. Neurol. 68, 611-618. doi: 10.1002/ana.22122
88. Kruer, M. C., Salih, M. A., Mooney, C., Alzahrani, J., Elmalik, S. A., Kabiraj, M. M., et al. (2014). C19orf12 mutation leads to a pallido-pyramidal syndrome. Gene 537, 352-356. doi: 10.1016/j.gene.2013.11.039
89. Kubota, A., Hida, A., Ichikawa, Y., Momose, Y., Goto, J., Igeta, Y., et al. (2009). A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov. Disord. 24, 441-445. doi: 10.1002/mds.22435
90. Kuo, Y. M., Duncan, J. L., Westaway, S. K., Yang, H., Nune, G., Xu, E. Y., et al. (2005). Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Hum. Mol. Genet. 14, 49-57. doi: 10.1093/hmg/ddi005
91. Kurian, M. A., and Hayflick, S. J. (2013). Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes. Int. Rev. Neurobiol. 110, 49-71. doi: 10.1016/B978-0-12-410502-7.00003-X
92. Kurian, M. A., Morgan, N. V., MacPherson, L., Foster, K., Peake, D., Gupta, R., et al. (2008). Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 70, 1623-1629. doi: 10.1212/01.wnl.0000310986.48286.8e
93. Kwiatkowski, A., Ryckewaert, G., Jissendi Tchofo, P., Moreau, C., Vuillaume, I., Chinnery, P. F., et al. (2012). Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation. Parkinsonism Relat. Disord. 18, 110-112. doi: 10.1016/j.parkreldis.2011.06.024
94. Landouré, G., Zhu, P. P., Lourenço, C. M., Johnson, J. O., Toro, C., Bricceno, K. V., et al. (2013). Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12. Hum. Mutat. 34, 1357-1360. doi: 10.1002/humu.22378
95. Larsson, P. K., Claesson, H. E., and Kennedy, B. P. (1998). Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity. J. Biol. Chem. 273, 207-214. doi: 10.1074/jbc.273.1.207
96. Lawson, D. M., Artymiuk, P. J., Yewdall, S. J., Smith, J. M., Livingstone, J. C., Treffry, A., et al. (1991). Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature 349, 541-544. doi: 10.1038/349541a0
97. Lehn, A., Boyle, R., Brown, H., Airey, C., and Mellick, G. (2012). Neuroferritinopathy. Parkinsonism Relat. Disord. 18, 909-915. doi: 10.1016/j.parkreldis.2012.06.021
98. Leonardi, R., Rock, C. O., Jackowski, S., and Zhang, Y. M. (2007a). Activation of human mitochondrial pantothenate kinase 2 by palmitoylcarnitine. Proc. Natl. Acad. Sci. U.S.A. 104, 1494-1499. doi: 10.1073/pnas.0607621104
99. Leonardi, R., Zhang, Y. M., Lykidis, A., Rock, C. O., and Jackowski, S. (2007b). Localization and regulation of mouse pantothenate kinase 2. FEBS Lett. 581, 4639-4644. doi: 10.1016/j.febslet.2007.08.056
100. Leonardi, R., Zhang, Y. M., Rock, C. O., and Jackowski, S. (2005). Coenzyme A: back in action. Prog. Lipid Res. 44, 125-153. doi: 10.1016/j.plipres.2005.04.001
101. Levi, S., Santambrogio, P., Cozzi, A., Rovida, E., Corsi, B., Tamborini, E., et al. (1994). The role of the L-chain in ferritin iron incorporation. Studies of homo and heteropolymers. J. Mol. Biol. 238, 649-654. doi: 10.1006/jmbi.1994.1325
102. Lu, Q., Yang, P., Huang, X., Hu, W., Guo, B., Wu, F., et al. (2011). The WD40 repeat PtdIns(3)P-binding protein EPG-6 regulates progression of omegasomes to autophagosomes. Dev. Cell 21, 343-357. doi: 10.1016/j.devcel.2011.06.024
103. Luscieti, S., Santambrogio, P., Langlois d'Estaintot, B., Granier, T., Cozzi, A., Poli, M., et al. (2010). Mutant ferritin L-chains that cause neurodegeneration act in a dominant-negative manner to reduce ferritin iron incorporation. J. Biol. Chem. 285, 11948-11957. doi: 10.1074/jbc.M109.096404
104. Maciel, P., Cruz, V. T., Constante, M., Iniesta, I., Costa, M. C., Gallati, S., et al. (2005). Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology 65, 603-605. doi: 10.1212/01.wnl.0000178224.81169.c2
105. Malik, I., Turk, J., Mancuso, D. J., Montier, L., Wohltmann, M., Wozniak, D. F., et al. (2008). Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am. J. Pathol. 172, 406-416. doi: 10.2353/ajpath.2008.070823
106. Mancuso, M., Davidzon, G., Kurlan, R. M., Tawil, R., Bonilla, E., Di Mauro, S., et al. (2005). Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J. Neuropathol. Exp. Neurol. 64, 280-294.
107. Mariani, R., Arosio, C., Pelucchi, S., Grisoli, M., Piga, A., Trombini, P., et al. (2004). Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation. Gut 53, 756-758. doi: 10.1136/gut.2003.030429
108. McNeill, A., Birchall, D., Hayflick, S. J., Gregory, A., Schenk, J. F., Zimmerman, E. A., et al. (2008). T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 70, 1614-1619. doi: 10.1212/01.wnl.0000310985.40011.d6
109. Miyajima, H. (2003). Aceruloplasminemia, an iron metabolic disorder. Neuropathology 23, 345-350. doi: 10.1046/j.1440-1789.2003.00521.x
110. Miyajima, H., Nishimura, Y., Mizoguchi, K., Sakamoto, M., Shimizu, T., and Honda, N. (1987). Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. Neurology 37, 761-767. doi: 10.1212/WNL.37.5.761
111. Morgan, N. V., Westaway, S. K., Morton, J. E., Gregory, A., Gissen, P., Sonek, S., et al. (2006). PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 38, 752-754. doi: 10.1038/ng1826
112. Morita, H., Ikeda, S., Yamamoto, K., Morita, S., Yoshida, K., Nomoto, S., et al. (1995). Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family. Ann. Neurol. 37, 646-656. doi: 10.1002/ana.410370515
113. Muhoberac, B. B., Baraibar, M. A., and Vidal, R. (2011). Iron loading-induced aggregation and reduction of iron incorporation in heteropolymeric ferritin containing a mutant light chain that causes neurodegeneration. Biochim. Biophys. Acta 1812, 544-548. doi: 10.1016/j.bbadis.2010.10.010
114. Neumann, M., Adler, S., Schlüter, O., Kremmer, E., Benecke, R., and Kretzschmar, H. A. (2000). Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol. 100, 568-574.
115. Ogimoto, M., Anzai, K., Takenoshita, H., Kogawa, K., Akehi, Y., Yoshida, R., et al. (2011). Criteria for early identification of aceruloplasminemia. Intern. Med. 50, 1415-1418. doi: 10.2169/internalmedicine.50.5108
116. Ohta, E., and Takiyama, Y. (2012). MRI findings in neuroferritinopathy. Neurol. Res. Int. 2012, 197438. doi: 10.1155/2012/197438
117. Ohta, E., Nagasaka, T., Shindo, K., Toma, S., Nagasaka, K., Ohta, K., et al. (2008). Neuroferritinopathy in a Japanese family with a duplication in the ferritin light chain gene. Neurology 70(16 Pt 2), 1493-1494. doi: 10.1212/01.wnl.0000310428.74624.95
118. Paisán-Ruiz, C., Li, A., Schneider, S. A., Holton, J. L., Johnson, R., Kidd, D., et al. (2012). Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol. Aging 33, 814-823. doi: 10.1016/j.neurobiolaging.2010.05.009
119. Pandey, V., Varun, P., Turm, H., Hagit, T., Bekenstein, U., Uriya, B., et al. (2013). A new in vivo model of pantothenate kinase-associated neurodegeneration reveals a surprising role for transcriptional regulation in pathogenesis. Front. Cell. Neurosci. 7:146. doi: 10.3389/fncel.2013.00146
120. Panteghini, C., Zorzi, G., Venco, P., Dusi, S., Reale, C., Brunetti, D., et al. (2012). C19orf12 and FA2H mutations are rare in Italian patients with neurodegeneration with brain iron accumulation. Semin. Pediatr. Neurol. 19, 75-81. doi: 10.1016/j.spen.2012.03.006
121. Park, J. S., Koentjoro, B., Veivers, D., Mackay-Sim, A., and Sue, C. M. (2014). Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum. Mol. Genet. doi: 10.1093/hmg/ddt623 [Epub ahead of print].
122. Patel, B. N., Dunn, R. J., and David, S. (2000). Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J. Biol. Chem. 275, 4305-4310. doi: 10.1074/jbc.275.6.4305
123. Patel, B. N., Dunn, R. J., Jeong, S. Y., Zhu, Q., Julien, J. P., and David, S. (2002). Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J. Neurosci. 22, 6578-6586.
124. Patil, V. A., Fox, J. L., Gohil, V. M., Winge, D. R., and Greenberg, M. L. (2013). Loss of cardiolipin leads to perturbation of mitochondrial and cellular iron homeostasis. J. Biol. Chem. 288, 1696-1705. doi: 10.1074/jbc.M112.428938
125. Pérez, R., Balboa, M. A., and Balsinde, J. (2006). Involvement of group VIA calcium-independent phospholipase A2 in macrophage engulfment of hydrogen peroxide-treated U937 cells. J. Immunol. 176, 2555-2561. doi: 10.4049/jimmunol.176.4.2555
126. Perry, T. L., Norman, M. G., Yong, V. W., Whiting, S., Crichton, J. U., Hansen, S., et al. (1985). Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann. Neurol. 18, 482-489. doi: 10.1002/ana.410180411
127. Poli, M., Derosas, M., Luscieti, S., Cavadini, P., Campanella, A., Verardi, R., et al. (2010). Pantothenate kinase-2 (Pank2) silencing causes cell growth reduction, cell-specific ferroportin upregulation and iron deregulation. Neurobiol. Dis. 39, 204-210. doi: 10.1016/j.nbd.2010.04.009
128. Polster, B. J., Yoon, M. Y., and Hayflick, S. J. (2010). Characterization of the human PANK2 promoter. Gene 465, 53-60. doi: 10.1016/j.gene.2010.06.011
129. Potter, K. A., Kern, M. J., Fullbright, G., Bielawski, J., Scherer, S. S., Yum, S. W., et al. (2011). Central nervous system dysfunction in a mouse model of FA2H deficiency. Glia 59, 1009-1021. doi: 10.1002/glia.21172
130. Ramonet, D., Podhajska, A., Stafa, K., Sonnay, S., Trancikova, A., Tsika, E., et al. (2012). PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. Hum. Mol. Genet. 21, 1725-1743. doi: 10.1093/hmg/ddr606
131. Rana, A., Seinen, E., Siudeja, K., Muntendam, R., Srinivasan, B., van der Want, J. J., et al. (2010). Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 107, 6988-6993. doi: 10.1073/pnas.0912105107
132. Roberti Mdo, R., Borges Filho, H. M., Goncalves, C. H., and Lima, F. L. (2011). Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases. Rev. Bras. Hematol. Hemoter. 33, 389-392. doi: 10.5581/1516-8484.20110104
133. Rouault, T. A. (2012). Biogenesis of iron-sulfur clusters in mammalian cells: new insights and relevance to human disease. Dis. Model. Mech. 5, 155-164. doi: 10.1242/dmm.009019
134. Rouault, T. A. (2013). Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat. Rev. Neurosci. 14, 551-564. doi: 10.1038/nrn3453
135. Saitsu, H., Nishimura, T., Muramatsu, K., Kodera, H., Kumada, S., Sugai, K., et al. (2013). De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat. Genet. 45, 445-449, 449e1. doi: 10.1038/ng.2562
136. Santambrogio, P., Levi, S., Cozzi, A., Rovida, E., Albertini, A., and Arosio, P. (1993). Production and characterization of recombinant heteropolymers of human ferritin H and L chains. J. Biol. Chem. 268, 12744-12748.
137. Schneider, S. A., Paisan-Ruiz, C., Quinn, N. P., Lees, A. J., Houlden, H., Hardy, J., et al. (2010). ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov. Disord. 25, 979-984. doi: 10.1002/mds.22947
138. Schneider, S. A., Zorzi, G., and Nardocci, N. (2013). Pathophysiology and treatment of neurodegeneration with brain iron accumulation in the pediatric population. Curr. Treat. Options Neurol. 15, 652-667. doi: 10.1007/s11940-013-0254-5
139. Schultheis, P. J., Fleming, S. M., Clippinger, A. K., Lewis, J., Tsunemi, T., Giasson, B., et al. (2013). Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited a-synuclein accumulation and age-dependent sensorimotor deficits. Hum. Mol. Genet. 22, 2067-2082. doi: 10.1093/hmg/ddt057
140. Schulz, K., Vulpe, C. D., Harris, L. Z., and David, S. (2011). Iron efflux from oligodendrocytes is differentially regulated in gray and white matter. J. Neurosci. 31, 13301-13311. doi: 10.1523/JNEUROSCI.2838-11.2011
141. Seleznev, K., Zhao, C., Zhang, X. H., Song, K., and Ma, Z. A. (2006). Calcium-independent phospholipase A2 localizes in and protects mitochondria during apoptotic induction by staurosporine. J. Biol. Chem. 281, 22275-22288. doi: 10.1074/jbc.M604330200
142. Sethi, K. D., Adams, R. J., Loring, D. W., and el Gammal, T. (1988). Hallervorden-Spatz syndrome: clinical and magnetic resonance imaging correlations. Ann. Neurol. 24, 692-694. doi: 10.1002/ana.410240519
143. Shinzawa, K., Sumi, H., Ikawa, M., Matsuoka, Y., Okabe, M., Sakoda, S., et al. (2008). Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J. Neurosci. 28, 2212-2220. doi: 10.1523/JNEUROSCI.4354-07.2008
144. Shinzawa, K., and Tsujimoto, Y. (2003). PLA2 activity is required for nuclear shrinkage in caspase-independent cell death. J. Cell Biol. 163, 1219-1230. doi: 10.1083/jcb.200306159
145. Siudeja, K., Grzeschik, N. A., Rana, A., de Jong, J., and Sibon, O. C. (2012). Cofilin/twinstar phosphorylation levels increase in response to impaired coenzyme a metabolism. PLoS ONE 7:e43145. doi: 10.1371/journal.pone.0043145
146. Siudeja, K., Srinivasan, B., Xu, L., Rana, A., de Jong, J., Nollen, E. A., et al. (2011). Impaired coenzyme A metabolism affects histone and tubulin acetylation in Drosophila and human cell models of pantothenate kinase associated neurodegeneration. EMBO Mol. Med. 3, 755-766. doi: 10.1002/emmm.201100180
147. Skidmore, F. M., Drago, V., Foster, P., Schmalfuss, I. M., Heilman, K. M., and Streiff, R. R. (2008). Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation. J. Neurol. Neurosurg. Psychiatry 79, 467-470. doi: 10.1136/jnnp.2007.120568
148. Smani, T., Zakharov, S. I., Csutora, P., Leno, E., Trepakova, E. S., and Bolotina, V. M. (2004). A novel mechanism for the store-operated calcium influx pathway. Nat. Cell Biol. 6, 113-120. doi: 10.1038/ncb1089
149. Storti, E., Cortese, F., Di Fabio, R., Fiorillo, C., Pierallini, A., Tessa, A., et al. (2013). De novo FTL mutation: a clinical, neuroimaging, and molecular study. Mov. Disord. 28, 252-253. doi: 10.1002/mds.25275
150. Strokin, M., Seburn, K. L., Cox, G. A., Martens, K. A., and Reiser, G. (2012). Severe disturbance in the Ca2+ signaling in astrocytes from mouse models of human infantile neuroaxonal dystrophy with mutated Pla2g6. Hum. Mol. Genet. 21, 2807-2814. doi: 10.1093/hmg/dds108
151. Tahiliani, A. G., and Neely, J. R. (1987). Mitochondrial synthesis of coenzyme A is on the external surface. J. Mol. Cell. Cardiol. 19, 1161-1167. doi: 10.1016/S0022-2828(87)80526-6
152. Tan, J., Zhang, T., Jiang, L., Chi, J., Hu, D., Pan, Q., et al. (2011). Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. J. Biol. Chem. 286, 29654-29662. doi: 10.1074/jbc.M111.233874
153. Tang, J., Kriz, R. W., Wolfman, N., Shaffer, M., Seehra, J., and Jones, S. S. (1997). A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs. J. Biol. Chem. 272, 8567-8575. doi: 10.1074/jbc.272.13.8567
154. Texel, S. J., Camandola, S., Ladenheim, B., Rothman, S. M., Mughal, M. R., Unger, E. L., et al. (2012). Ceruloplasmin deficiency results in an anxiety phenotype involving deficits in hippocampal iron, serotonin, and BDNF. J. Neurochem. 120, 125-134. doi: 10.1111/j.1471-4159.2011.07554.x
155. Tsunemi, T., and Krainc, D. (2013). Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum Mol. Genet. doi: 10.1093/hmg/ddt572 [Epub ahead of print].
156. Usenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P., and Krainc, D. (2012). Deficiency of ATP13A2 leads to lysosomal dysfunction, a-synuclein accumulation, and neurotoxicity. J. Neurosci. 32, 4240-4246. doi: 10.1523/JNEUROSCI.5575-11.2012
157. Vidal, R., Ghetti, B., Takao, M., Brefel-Courbon, C., Uro-Coste, E., Glazier, B. S., et al. (2004). Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J. Neuropathol. Exp. Neurol. 63, 363-380.
158. Vidal, R., Miravalle, L., Gao, X., Barbeito, A. G., Baraibar, M. A., Hekmatyar, S. K., et al. (2008). Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J. Neurosci. 28, 60-67. doi: 10.1523/JNEUROSCI.3962-07.2008
159. Wada, H., Yasuda, T., Miura, I., Watabe, K., Sawa, C., Kamijuku, H., et al. (2009). Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6. Am. J. Pathol. 175, 2257-2263. doi: 10.2353/ajpath.2009.090343
160. Wakabayashi, K., Fukushima, T., Koide, R., Horikawa, Y., Hasegawa, M., Watanabe, Y., et al. (2000). Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology. Acta Neuropathol. 99, 331-336. doi: 10.1007/s004010050049
161. Wang, J., Jiang, H., and Xie, J. X. (2007). Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur. J. Neurosci. 25, 2766-2772. doi: 10.1111/j.1460-9568.2007.05515.x
162. Williams, S. D., and Gottlieb, R. A. (2002). Inhibition of mitochondrial calcium-independent phospholipase A2 (iPLA2) attenuates mitochondrial phospholipid loss and is cardioprotective. Biochem. J. 362(Pt 1), 23-32. doi: 10.1042/0264-6021:3620023
163. Wills, A. J., Sawle, G. V., Guilbert, P. R., and Curtis, A. R. (2002). Palatal tremor and cognitive decline in neuroferritinopathy. J. Neurol. Neurosurg. Psychiatry 73, 91-92. doi: 10.1136/jnnp.73.1.91
164. Winstead, M. V., Balsinde, J., and Dennis, E. A. (2000). Calcium-independent phospholipase A(2): structure and function. Biochim. Biophys. Acta 1488, 28-39. doi: 10.1016/S1388-1981(00)00107-4
165. Wolkow, N., Song, D., Song, Y., Chu, S., Hadziahmetovic, M., Lee, J. C., et al. (2012). Ferroxidase hephaestin's cell-autonomous role in the retinal pigment epithelium. Am. J. Pathol. 180, 1614-1624. doi: 10.1016/j.ajpath.2011.12.041
166. Wu, Y., Jiang, Y., Gao, Z., Wang, J., Yuan, Y., Xiong, H., et al. (2009a). Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy. Eur. J. Neurol. 16, 240-245. doi: 10.1111/j.1468-1331.2008.02397.x
167. Wu, Z., Li, C., Lv, S., and Zhou, B. (2009b). Pantothenate kinase-associated neurodegeneration: insights from a Drosophila model. Hum. Mol. Genet. 18, 3659-3672. doi: 10.1093/hmg/ddp314
168. Yamamoto, K., Yoshida, K., Miyagoe, Y., Ishikawa, A., Hanaoka, K., Nomoto, S., et al. (2002). Quantitative evaluation of expression of iron-metabolism genes in ceruloplasmin-deficient mice. Biochim. Biophys. Acta 1588, 195-202. doi: 10.1016/S0925-4439(02)00165-5
169. Yang, H. C., Mosior, M., Johnson, C. A., Chen, Y., and Dennis, E. A. (1999). Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal. Biochem. 269, 278-288. doi: 10.1006/abio.1999.4053
170. Yoshida, K., Furihata, K., Takeda, S., Nakamura, A., Yamamoto, K., Morita, H., et al. (1995). A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat. Genet. 9, 267-272. doi: 10.1038/ng0395-267
171. Zhang, X. H., Zhao, C., Seleznev, K., Song, K., Manfredi, J. J., and Ma, Z. A. (2006a). Disruption of G1-phase phospholipid turnover by inhibition of Ca2+-independent phospholipase A2 induces a p53-dependent cell-cycle arrest in G1 phase. J. Cell Sci. 119(Pt 6), 1005-1015. doi: 10.1242/jcs.02821
172. Zhang, Y. M., Rock, C. O., and Jackowski, S. (2006b). Biochemical properties of human pantothenate kinase 2 isoforms and mutations linked to pantothenate kinase-associated neurodegeneration. J. Biol. Chem. 281, 107-114. doi: 10.1074/jbc.M508825200
173. Zhou, B., Westaway, S. K., Levinson, B., Johnson, M. A., Gitschier, J., and Hayflick, S. J. (2001). A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat. Genet. 28, 345-349. doi: 10.1038/ng572
174. Zhyvoloup, A., Nemazanyy, I., Babich, A., Panasyuk, G., Pobigailo, N., Vudmaska, M., et al. (2002). Molecular cloning of CoA synthase. The missing link in CoA biosynthesis. J. Biol. Chem. 277, 22107-22110. doi: 10.1074/jbc.C200195200
175. Zöller, I., Meixner, M., Hartmann, D., Büssow, H., Meyer, R., Gieselmann, V., et al. (2008). Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. J. Neurosci. 28, 9741-9754. doi: 10.1523/JNEUROSCI.0458-08.2008
176. Zorzi, G., Zibordi, F., Chiapparini, L., Bertini, E., Russo, L., Piga, A., et al. (2011). Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov. Disord. 26, 1756-1759. doi: 10.1002/mds.23751